Seppic presents its adjuvant systems for therapeutic vaccines at SITC
Seppic attended last november “The Society for Immunotherapy of Cancer” (SITC) congress that took place in National Harbor, Md. This Annual Meeting is the leading destination for scientific exchange, education and networking in the cancer immunotherapy field.
During the event, promising data have been shared in various immunotherapeutic fields including vaccination, combo treatments (exp: therapeutic vaccination association with Check Point inhibitors), oncolytic viruses...with many scientific posters.
Seppic booth was dedicated to MONTANIDE™ ISA 51 VG and MONTANIDE™ ISA 720, our adjuvant systems dedicated to human therapeutic vaccines. These adjuvants are mainly dedicated to Immuno Oncology treatments (cancers). Take a look at our poster: “Safety and effectiveness of GMP grade MONTANIDE ISA 51 adjuvant for therapeutic vaccines”.